SAR-096: Phase II clinical trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS)
In previous studies, a combination of ribociclib (which inhibits a protein called CDK4 that regulates cell cycles) and everolimus (which inhibits a protein called mTOR that is involved in a cell signaling pathway) has shown synergistic growth inhibition in multiple tumor models. In the study, “SAR-096: Phase II clinical trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS),” investigators report that in a single arm, open label, multi-center phase II study in dedifferentiated liposarcoma (DDL) and leiomyosarcoma (LMS), the combination demonstrated activity in DDL with prolonged stable disease and 2 partial responses, but not in LMS. The combination was well-tolerated with expected side effects.